TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.

Fiche publication

Date publication

août 2024

Journal

Future oncology (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MANSI Laura , Dr FAVIER Laure , Dr EBERST Lauriane

Tous les auteurs :
Kabirian R, Tredan O, Marmé F, Paoletti X, Eberst L, Lebreton C, La Motte Rouge T, Sabatier R, Angelergues A, Fabbro M, Gorp TV, Mansi L, Gladieff L, Kaczmarek E, Alexandre J, Grellety T, Favier L, Welz J, Frenel JS, Leary A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39155847

Résumé

Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are offered to prolong intervals between lines of chemotherapy. Current maintenance options involve bevacizumab and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be used once in the disease course. Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy. NCT04713514 (ClinicalTrials.gov).